Equities

Myriad Genetics Inc

Myriad Genetics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)15.49
  • Today's Change0.37 / 2.45%
  • Shares traded672.57k
  • 1 Year change-12.49%
  • Beta1.8975
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

  • Revenue in USD (TTM)823.60m
  • Net income in USD-116.00m
  • Incorporated1992
  • Employees2.70k
  • Location
    Myriad Genetics Inc322 North 2200 WestSALT LAKE CITY 84116United StatesUSA
  • Phone+1 (801) 584-3600
  • Fax+1 (801) 584-3640
  • Websitehttps://myriad.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pulse Biosciences Inc0.00-46.13m1.09bn56.00--13.74-----0.8069-0.80690.001.290.00----0.00-58.03-93.21-62.84-104.99-------12,332.25----0.00---100.00--27.85---15.20--
Artivion Inc384.90m-846.00k1.19bn1.50k--3.8951.813.08-0.0235-0.02359.257.270.48791.685.50256,599.30-0.1079-2.20-0.1242-2.3664.5365.51-0.2211-5.341.331.100.51--12.826.14-60.09--5.13--
BioLife Solutions Inc118.41m-26.44m1.20bn409.00--3.69--10.13-0.5826-1.012.597.040.29871.695.58289,513.40-6.67-13.76-7.37-15.0446.1536.76-22.33-42.991.78-4.030.0614---11.4348.6552.49--86.35--
Establishment Labs Holdings Inc153.07m-70.61m1.21bn933.00--36.83--7.88-2.58-2.585.571.170.55340.79162.51168,580.40-25.53-33.22-31.21-41.1265.0864.73-46.13-43.192.29-4.510.856--2.1321.96-4.38--69.16--
Evolent Health Inc2.46bn-104.23m1.31bn4.70k--1.2590.000.5322-0.9129-0.912921.5510.660.953--6.14524,309.40-2.79-9.60-3.58-12.5915.9624.50-2.93-13.66---0.55950.3285--45.2625.65-660.71---6.18--
STAAR Surgical Co341.22m21.78m1.31bn1.06k60.903.0747.533.850.43810.43816.908.690.67632.033.15323,128.804.326.774.927.9078.7376.896.389.165.38--0.00020.0013.3721.07-46.1833.8551.95--
Adapthealth Corp3.26bn-217.76m1.33bn10.70k--0.87448.050.4064-1.64-1.6424.2311.270.709621.158.45304,912.50-4.57-4.34-5.14-4.8919.0318.28-6.44-6.470.99512.290.5757--7.73---1,169.99------
Myriad Genetics, Inc.823.60m-116.00m1.41bn2.70k--1.93--1.71-1.30-1.309.218.040.73859.916.84305,037.00-10.40---12.43--69.15---14.08--1.73-105.000.0506--11.03---135.09------
Alphatec Holdings Inc572.74m-177.87m1.43bn839.00------2.49-1.27-1.274.080.15460.80891.117.73682,644.80-25.12-30.97-32.00-39.4769.4766.02-31.06-46.221.15-3.660.9596--37.4539.38-23.36--67.92--
Inmode Ltd423.75m153.67m1.45bn581.0010.302.139.403.421.851.855.048.920.52391.5810.15729,339.1019.0031.3220.7735.6481.6484.4636.2639.659.91--0.000.008.3237.4922.5454.6513.10--
10X Genomics Inc629.74m-182.55m1.73bn1.26k--2.40--2.75-1.53-1.535.265.970.66772.406.72500,193.00-19.36-25.52-21.99-29.0566.6375.88-28.99-48.534.12--0.00--19.8133.43-53.67--49.15--
AtriCure Inc447.57m-38.92m1.74bn1.20k--3.75--3.89-0.8322-0.83229.569.540.73651.638.41372,977.50-6.40-3.72-7.35-4.1074.7974.36-8.70-7.642.59-13.760.1194--20.8414.6434.49--46.56--
Patterson Companies, Inc.6.53bn168.41m1.80bn7.60k11.181.896.990.2761.831.8371.2210.802.275.8615.35859,640.705.841.1310.151.8121.0320.982.570.51570.67237.910.4474304.751.503.34-10.4218.102.170.00
Rxsight Inc128.29m-30.69m1.81bn374.00--6.51--14.08-0.8194-0.81943.406.890.52121.996.32343,029.40-12.47---13.62--68.44---23.92--11.71--0.0005--81.77--27.19------
Integra Lifesciences Holdings Corp1.56bn-6.54m1.82bn3.95k--1.2014.241.16-0.0881-0.088120.2219.730.4011.595.99396,583.90-0.16773.33-0.20023.6859.2963.67-0.41827.990.72614.050.54280.00-1.030.9219-62.482.19-2.97--
Data as of Nov 22 2024. Currency figures normalised to Myriad Genetics Inc's reporting currency: US Dollar USD

Institutional shareholders

61.01%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 202413.87m15.27%
The Vanguard Group, Inc.as of 30 Sep 202410.15m11.17%
Wellington Management Co. LLPas of 30 Sep 20246.05m6.66%
Millennium Management LLCas of 30 Sep 20245.18m5.70%
SSgA Funds Management, Inc.as of 30 Sep 20244.70m5.18%
EARNEST Partners LLCas of 30 Sep 20243.96m4.36%
Camber Capital Management LPas of 30 Sep 20243.95m4.35%
Managed Account Advisors LLCas of 30 Sep 20242.60m2.87%
Disciplined Growth Investors, Inc.as of 30 Sep 20242.53m2.78%
Artisan Partners LPas of 30 Sep 20242.43m2.68%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.